Naloxone intranasal spray - INSYS Therapeutics

Drug Profile

Naloxone intranasal spray - INSYS Therapeutics

Alternative Names: Naloxone nasal spray - INSYS Therapeutics

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Opioid abuse

Most Recent Events

  • 18 Oct 2017 Chemical structure information added
  • 04 Oct 2017 Phase-I clinical trials in Opioid abuse in USA (Intranasal) (INSYS Therapeutics pipeline, October 2017)
  • 03 Oct 2017 INSYS Therapeutics announces intention to submit NDA to the US FDA for Opioid abuse in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top